U.S. Electronic Equipment and Components Stock News

Pharvaris N.V. recently completed a follow-on equity offering of 3,874,664 ordinary shares at US$29.68 per share, raising about US$115.00 million in gross proceeds, after earlier announcing the transaction and granting underwriters a 30-day option to buy up to 581,199 additional shares. The deal, coming shortly after the Chief Medical Officer’s cashless exercise and sale of stock options, highlights both the company’s drive to bolster its cash position and the active role of insiders in...

In April 2026, Olema Pharmaceuticals appointed Prakash Raman, Ph.D., a veteran biopharma executive and current CEO of InduPro Therapeutics, to its Board of Directors. Raman’s extensive background in oncology collaborations and deal-making at Novartis, Flagship Pioneering, and multiple biotech leadership roles adds significant business development depth to Olema’s governance. Next, we will examine how Raman’s oncology-focused business development experience could influence Olema...

In early May 2026, Paychex, Inc. raised its regular quarterly cash dividend to US$1.19 per share, a US$0.11 (10%) increase from the prior US$1.08, payable on May 29, 2026 to shareholders of record on May 13, 2026. Around the same time, the company’s Small Business Employment Watch showed a second straight month of improving U.S. small-business job growth, highlighting resilience in Paychex’s core client base. Next, we’ll examine how this 10% dividend increase could influence Paychex’s...

CDW (NasdaqGS:CDW) has launched an AI first program called "Geared for Growth" across its operations and go to market model. The initiative seeks up to US$200 million in annual run rate savings targeted for 2027 to 2028. The program focuses on embedding AI into internal processes and customer facing activities to improve productivity and efficiency. CDW is a technology solutions provider, so an AI first shift sits directly in the flow of what customers are asking for across infrastructure,...

Why Proto Labs Stock Is Drawing Attention Now Proto Labs (PRLB) is back on many investors’ radar after a recent share price move, with the stock showing a return of about 18% over the past month and 33% year to date. See our latest analysis for Proto Labs. The recent 1 month share price return of 18.5% and year to date share price return of 32.8% come on top of a 1 year total shareholder return of 69.6%, suggesting momentum has been building rather than fading. If Proto Labs has caught your...

Wondering if Plains All American Pipeline at around US$22 is still offering value, or if most of the opportunity is already priced in. The stock last closed at US$22.09, with a 4% decline over the past week, a 0.7% decline over the past month, a 21.3% gain year to date and a 41.7% return over the past year. Recent coverage around Plains All American Pipeline has focused on its position within the energy infrastructure space and how investors are weighing income potential against exposure to...

CoreCivic stock: why recent returns are catching investor attention CoreCivic (CXW) has been drawing fresh interest after a stretch of mixed returns, with gains over the past month and past 3 months alongside a slightly negative 1 year total return. For readers tracking performance, the stock shows a 3.1% 1 day return, 6.6% over the past week, 9.2% over the past month and 16.6% over the past 3 months, while the 1 year total return sits at about a 0.9% decline. See our latest analysis for...

In the past quarter, Carrier Global Corporation reported first quarter 2026 revenue of US$5,341 million versus US$5,218 million a year earlier, while net income fell to US$238 million from US$412 million, and the company reaffirmed its full‑year 2026 sales outlook of about US$22.00 billion. Management highlighted that global data center orders increased by a very large amount year over year, with backlog already covering the US$1.50 billion data center sales target for 2026 and aftermarket...

Wondering if Paycom Software at around US$138 a share is a bargain or a value trap? This article walks through what the current price actually implies. The stock has shown a 9.2% return over the last 7 days and 11.4% over the last 30 days. Yet year to date it sits at a 9.2% loss and a 44.0% loss over the past year, which naturally raises questions about risk and potential recovery. Recent coverage has focused on how Paycom Software fits into the broader professional services and software...

In late April 2026, FactSet Research Systems Inc. and J.P. Morgan announced the launch of a Whole Portfolio Distribution solution, giving institutional investors a unified, automated view of portfolios across asset classes and data sources through FactSet, powered by Fusion by J.P. Morgan and already supporting US$62.50 billion in Assets under Analysis. In early May 2026, FactSet Research Systems Inc. also approved a higher quarterly dividend of US$1.16 per share payable on June 18, 2026,...

Equifax (EFX) stock has been moving without a clear single news catalyst, leaving investors focused on its recent share performance, current valuation signals, and the latest snapshot of its business fundamentals. See our latest analysis for Equifax. At a share price of $175.62, Equifax has seen a 1-day share price return of 1.40%. Its year to date share price return of 17.95% and 1-year total shareholder return of 34.65% indicate changing momentum following earlier weakness. If you are...

CTS (CTS) has caught investor attention after first quarter 2026 earnings exceeded analyst expectations and management raised full year sales guidance, prompting closer scrutiny of what is driving the stock at recent highs. See our latest analysis for CTS. The recent 1 month share price return of 21.01% and year to date share price return of 36.49% suggest momentum has been building, supported by first quarter earnings, raised 2026 sales guidance and continued buybacks. The 1 year total...

VICI Properties (VICI) just posted first quarter 2026 results, reporting revenue of US$1.02b and net income of US$872.39m, and raised full year AFFO guidance on the back of acquisitions and lending activity. See our latest analysis for VICI Properties. At a share price of US$28.79, VICI’s 30 day share price return of 3.45% contrasts with a 1 year total shareholder return of 3.24% decline. This suggests recent momentum is improving after a softer year, as investors weigh the raised AFFO...

Multiple securities fraud class action lawsuits have been filed against Pinterest (NYSE:PINS), targeting the company and certain executives. The suits claim Pinterest misled investors about advertising revenue pressures, the effects of U.S. tariffs, and upcoming restructuring plans. These cases are at an early stage, with a lead plaintiff deadline still pending. Pinterest runs a visual discovery platform that connects users with products and ideas, and its business model relies heavily on...

Schrödinger (SDGR) is back in focus after first quarter 2026 results combined a reported earnings miss with 12% growth in Annual Contract Value, along with fresh attention on its upcoming Bunsen AI co-scientist launch. See our latest analysis for Schrödinger. Recent trading reflects this renewed interest, with a 1 month share price return of 16.59% and 7 day share price return of 11.04%. However, the year to date share price return of negative 26.14% and 1 year total shareholder return of...

With no clear single event driving headlines, Archer Aviation (ACHR) has still drawn attention as the stock shifted from a recent monthly gain to a decline over the past three months and the past year. See our latest analysis for Archer Aviation. Archer Aviation's recent share price return shows short term momentum, with a 7 day gain of 9.41% and a 30 day gain of 17.60%. However, this follows a 90 day share price decline of 13.97% and a 1 year total shareholder return of 28.31% in the red...

ACM Research (ACMR) opened 2026 with Q1 revenue of US$231.3 million and basic EPS of US$0.26, alongside trailing twelve month revenue of US$960.2 million and EPS of US$1.40 that frame the latest quarterly print. Over the past six quarters, the company has seen quarterly revenue range from US$172.3 million to US$269.2 million and basic EPS move between US$0.12 and US$0.56, giving investors a clear view of how top line and per share earnings have tracked into the current TTM profile. With...

CG Oncology (CGON) has just closed out FY 2025 with Q4 revenue of US$2.3 million and a basic EPS loss of US$0.52, alongside a net income loss of US$41.3 million, as the company continues to invest heavily in its pipeline. Over the last twelve months, revenue has summed to US$4.0 million and basic EPS has come in at a loss of US$2.08. This gives investors a clear view of a business that is still in a development phase and running with intentionally thin margins while it pushes its late stage...

If you are wondering whether Envista Holdings at US$24.29 offers good value or is already fully priced, the recent share performance gives you a useful starting point. The stock has pulled back 6.4% over the last 7 days and 4.0% over the last 30 days. It sits 12.0% higher year to date and 36.7% above where it was a year ago, while the 3 year and 5 year returns of 26.7% and 44.7% highlight a tougher longer term journey. Recent coverage has focused on Envista Holdings as a dental equipment and...

Assurant (AIZ) just paired a strong Q1 2026 earnings beat with higher full year guidance and continued share repurchases, putting the spotlight on how its Global Lifestyle driven momentum might affect the stock. See our latest analysis for Assurant. Despite the strong Q1 surprise and ongoing buybacks, Assurant’s recent trading has been mixed, with a 6.86% 1 month share price return but a 1.65% year to date share price decline. In contrast, the 1 year total shareholder return of 21.86% and 3...

Earnings picture during a key regulatory phase Vera Therapeutics (VERA) reported a first quarter net loss of US$121.03 million, compared with US$51.69 million a year earlier, as it pushes atacicept toward potential approval for IgA nephropathy. Basic and diluted loss per share from continuing operations came in at US$1.69, versus US$0.81 in the prior year period. This provides a snapshot of how much capital the company is currently investing ahead of the July 7, 2026 FDA decision. See our...

What PNC’s Recent Returns Tell You PNC Financial Services Group (PNC) has moved in different directions across timeframes, with a 1 day return of about a 1.4% decline, losses over the past 3 months, and a 1 year total return of 35.9%. See our latest analysis for PNC Financial Services Group. Recent share price moves have cooled slightly, with a 30 day share price return of 2.5% against a 90 day share price return of a 9.6% decline, while the 1 year total shareholder return of 36.0% and 3...

Wondering if Labcorp Holdings at around US$258 a share still offers value, or if most of the opportunity is already priced in? This article walks through the key signals you can use to judge that for yourself. The stock has been fairly steady over the last week with a 0.5% return, has a 4.1% decline over the past month, yet sits on a 4.8% return over 1 year and 41.6% over 3 years. This raises the question of whether the current price reflects the business fundamentals. Recent headlines...

How Avery Dennison (AVY) Has Been Trading Recently Avery Dennison (AVY) has seen mixed share performance recently, with a 0.7% decline over the past day, a 1% gain over the past week, and a 1.2% decline over the past month. Over the past 3 months, the stock shows a 13.6% decline, with a year to date return of negative 9.3% and a 1 year total return of negative 2.3%. Longer term, the 3 year total return stands at 1.5%, while the 5 year total return is negative 18.3%. See our latest analysis...